5 Key Takeaways

• 1

  Selective laser trabeculoplasty (SLT) should be considered as a first-line therapy for newly diagnosed primary open-angle glaucoma.

• 2

  Recent studies indicate that the effects of SLT may last longer than previously believed, with median durations exceeding 6 years.

• 3

  SLT can be safely and effectively repeated, providing a potential strategy for managing intraocular pressure.

• 4

  The COAST trial aims to explore optimal timing and frequency for repeating SLT procedures in glaucoma management.

• 5

  The findings from the LiGHT trial and other studies support the safety and efficacy of repeat SLT treatments.